This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and ...

The full results indicated that vepdeg is active in patients with ESR1 mutations (ESR1m) and is likely to receive approval. However, Leerink Partners expressed concerns about vepdeg’s position as a ...

The full results indicated that vepdeg is active in patients with ESR1 mutations (ESR1m) and is likely to receive approval. However, Leerink Partners expressed concerns about vepdeg’s position ...

Not all medicines and/or indications presented in this report may be approved for use in all countries. Please note data included in this report are based on EU data and may vary depending on local ...

But following exposure to endocrine and CDK4/6 inhibitor therapy, many patients quickly acquire ER mutations (ESR1m), leading to treatment resistance and leaving a significant unmet need.

But following exposure to endocrine and CDK4/6 inhibitor therapy, many patients quickly acquire ER mutations (ESR1m), leading to treatment resistance and leaving a significant unmet need. Pfizer’s and ...